Total Payments
$3,038
2022 Payments
$36.30
Companies
19
Transactions
157
Medicare Patients
1,132
Medicare Billing
$87,466
Payment Breakdown by Category
Food & Beverage$3,030 (99.8%)
Education$7.29 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,030 | 156 | 99.8% |
| Education | $7.29 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $879.62 | 50 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $559.02 | 16 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $553.02 | 34 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $208.32 | 2 | $0 (2019) |
| PFIZER INC. | $194.34 | 9 | $0 (2019) |
| Janssen Biotech, Inc. | $111.61 | 9 | $0 (2021) |
| Gilead Sciences, Inc. | $90.47 | 6 | $0 (2021) |
| Valeant Pharmaceuticals North America LLC | $86.98 | 6 | $0 (2017) |
| Braintree Laboratories, Inc. | $75.05 | 5 | $0 (2021) |
| RedHill Biopharma Inc. | $49.34 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $36.30 | 2 | ABBVIE INC. ($36.30) |
| 2021 | $739.79 | 30 | Takeda Pharmaceuticals U.S.A., Inc. ($360.52) |
| 2020 | $388.34 | 23 | Takeda Pharmaceuticals U.S.A., Inc. ($93.31) |
| 2019 | $904.23 | 40 | AbbVie, Inc. ($398.62) |
| 2018 | $535.70 | 39 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($194.47) |
| 2017 | $433.23 | 23 | Janssen Scientific Affairs, LLC ($125.00) |
All Payment Transactions
157 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/09/2022 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: VIROLOGY | ||||||
| 02/12/2022 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: VIROLOGY | ||||||
| 10/12/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $11.89 | General |
| Category: VIROLOGY | ||||||
| 08/11/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: VIROLOGY | ||||||
| 06/22/2021 | AbbVie Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/18/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $8.98 | General |
| Category: VIROLOGY | ||||||
| 06/16/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: Gastroenterology | ||||||
| 06/09/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: Gastroenterology | ||||||
| 06/02/2021 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/20/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: Gastroenterology | ||||||
| 05/20/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Gastroenterology | ||||||
| 05/13/2021 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: IMMUNOLOGY | ||||||
| 05/11/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: VIROLOGY | ||||||
| 04/27/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: Gastroenterology | ||||||
| 04/26/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Gastroenterology | ||||||
| 04/24/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: VIROLOGY | ||||||
| 04/22/2021 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: Immunology | ||||||
| 04/20/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $17.84 | General |
| 04/12/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.61 | General |
| 04/07/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Gastroenterology | ||||||
| 03/31/2021 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: IMMUNOLOGY | ||||||
| 03/24/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $11.08 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/23/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $10.87 | General |
| Category: VIROLOGY | ||||||
| 03/22/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $316.08 | General |
| 03/22/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 13 | 340 | 373 | $164,767 | $24,333 |
| 2020 | 16 | 792 | 922 | $409,303 | $63,133 |
Total Patients
1,132
Total Services
1,295
Medicare Billing
$87,466
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 29 | 29 | $40,368 | $5,571 | 13.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 16 | 16 | $17,280 | $2,672 | 15.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 49 | 49 | $9,506 | $2,562 | 27.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 30 | 30 | $6,120 | $2,393 | 39.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 44 | 47 | $6,486 | $2,167 | 33.4% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 14 | 14 | $15,120 | $1,956 | 12.9% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 25 | 25 | $19,625 | $1,885 | 9.6% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 28 | 28 | $20,160 | $1,636 | 8.1% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2021 | 49 | 79 | $9,480 | $1,434 | 15.1% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 13 | 13 | $15,054 | $1,134 | 7.5% |
| 43450 | Dilation of esophagus unguided | Facility | 2021 | 17 | 17 | $3,400 | $507.62 | 14.9% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 14 | 14 | $1,988 | $364.39 | 18.3% |
| 82272 | Stool analysis for blood, by peroxidase activity | Office | 2021 | 12 | 12 | $180.00 | $50.76 | 28.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 73 | 74 | $103,008 | $14,319 | 13.9% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2020 | 49 | 49 | $52,920 | $8,616 | 16.3% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 90 | 90 | $17,460 | $5,574 | 31.9% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 57 | 57 | $44,745 | $4,915 | 11.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 63 | 69 | $14,076 | $4,857 | 34.5% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 56 | 56 | $64,848 | $4,688 | 7.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 86 | 97 | $13,386 | $4,613 | 34.5% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2020 | 136 | 228 | $27,360 | $4,220 | 15.4% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 34 | 36 | $25,920 | $2,514 | 9.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2020 | 14 | 14 | $15,120 | $2,497 | 16.5% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 52 | 52 | $7,384 | $2,251 | 30.5% |
| 45378 | Diagnostic examination of large bowel using an endoscope | Facility | 2020 | 12 | 12 | $12,960 | $1,474 | 11.4% |
About Dr. Edward Brown, MD
Dr. Edward Brown, MD is a Gastroenterology healthcare provider based in Maryville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851354195.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edward Brown, MD has received a total of $3,038 in payments from pharmaceutical and medical device companies, with $36.30 received in 2022. These payments were reported across 157 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($3,030).
As a Medicare-enrolled provider, Brown has provided services to 1,132 Medicare beneficiaries, totaling 1,295 services with total Medicare billing of $87,466. Data is available for 2 years (2020–2021), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Maryville, TN
- Active Since 04/08/2006
- Last Updated 07/06/2016
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1851354195
Products in Payments
- XIFAXAN (Drug) $454.68
- STELARA (Biological) $297.40
- Humira (Biological) $272.67
- MAVYRET (Drug) $207.46
- XELJANZ (Drug) $194.34
- Mavyret (Drug) $126.72
- ENTYVIO (Biological) $119.91
- UCERIS (Drug) $105.68
- LINZESS (Drug) $47.94
- Amitiza (Drug) $44.74
- Creon (Drug) $41.25
- Entyvio (Biological) $40.87
- OCALIVA (Drug) $38.50
- XIFAXANIBSD (Drug) $36.51
- Trulance (Drug) $35.23
- HUMIRA (Biological) $34.79
- Talicia (Drug) $31.09
- SUPREP (Drug) $25.12
- REMICADE (Biological) $22.53
- Aemcolo (Drug) $18.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Maryville
Dr. William Lyles, Md, MD
Gastroenterology — Payments: $136,354
Gastroenterology $136,354
Dr. Sirisha Jasti, Md, MD
Gastroenterology — Payments: $8,224
Gastroenterology $8,224
Dr. Frank Wright, M.d, M.D
Gastroenterology — Payments: $8,206
Gastroenterology $8,206
Edmundo Rodriguez-Frias, Md, MD
Gastroenterology — Payments: $7,976
Gastroenterology $7,976
Dr. Jennifer Phemister, M.d, M.D
Gastroenterology — Payments: $5,666
Gastroenterology $5,666
Dr. Isaac Cline, M.d, M.D
Gastroenterology — Payments: $4,763
Gastroenterology $4,763